Efficacy and safety of dulaglutide in patients with absolute insulin deficiency

Objective. While dulaglutide has been approved inpatients with type 2 diabetes (T2DM) in combination with insulin, it has not been studied in insulin-deficient patients, not whether they have type 1 diabetes (T1DM) or T2DM. The aim of this study is to assess the efficacy and safety of dulaglutide 0....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kutoh Eiji, Hayashi Jyunka, Kuto Alexandra N.
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2019
Materias:	glp-1 agonist dulaglutide type 1 diabetes insulin deficiency Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/b286433da4974cd4b09087741399d287
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b286433da4974cd4b09087741399d287
record_format	dspace
spelling	oai:doaj.org-article:b286433da4974cd4b09087741399d2872021-12-02T17:49:32ZEfficacy and safety of dulaglutide in patients with absolute insulin deficiency1336-032910.2478/enr-2019-0019https://doaj.org/article/b286433da4974cd4b09087741399d2872019-07-01T00:00:00Zhttps://doi.org/10.2478/enr-2019-0019https://doaj.org/toc/1336-0329Objective. While dulaglutide has been approved inpatients with type 2 diabetes (T2DM) in combination with insulin, it has not been studied in insulin-deficient patients, not whether they have type 1 diabetes (T1DM) or T2DM. The aim of this study is to assess the efficacy and safety of dulaglutide 0.75 mg/once weekly (QW) in patients with absolute insulin deficiency (n=10).Kutoh EijiHayashi JyunkaKuto Alexandra N.Sciendoarticleglp-1 agonistdulaglutidetype 1 diabetesinsulin deficiencyDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENEndocrine Regulations, Vol 53, Iss 3, Pp 187-190 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	glp-1 agonist dulaglutide type 1 diabetes insulin deficiency Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	glp-1 agonist dulaglutide type 1 diabetes insulin deficiency Diseases of the endocrine glands. Clinical endocrinology RC648-665 Kutoh Eiji Hayashi Jyunka Kuto Alexandra N. Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
description	Objective. While dulaglutide has been approved inpatients with type 2 diabetes (T2DM) in combination with insulin, it has not been studied in insulin-deficient patients, not whether they have type 1 diabetes (T1DM) or T2DM. The aim of this study is to assess the efficacy and safety of dulaglutide 0.75 mg/once weekly (QW) in patients with absolute insulin deficiency (n=10).
format	article
author	Kutoh Eiji Hayashi Jyunka Kuto Alexandra N.
author_facet	Kutoh Eiji Hayashi Jyunka Kuto Alexandra N.
author_sort	Kutoh Eiji
title	Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
title_short	Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
title_full	Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
title_fullStr	Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
title_full_unstemmed	Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
title_sort	efficacy and safety of dulaglutide in patients with absolute insulin deficiency
publisher	Sciendo
publishDate	2019
url	https://doaj.org/article/b286433da4974cd4b09087741399d287
work_keys_str_mv	AT kutoheiji efficacyandsafetyofdulaglutideinpatientswithabsoluteinsulindeficiency AT hayashijyunka efficacyandsafetyofdulaglutideinpatientswithabsoluteinsulindeficiency AT kutoalexandran efficacyandsafetyofdulaglutideinpatientswithabsoluteinsulindeficiency
_version_	1718379427855859712

Efficacy and safety of dulaglutide in patients with absolute insulin deficiency

Ejemplares similares